Quick Comparison
| Argireline (Acetyl Hexapeptide-3) | EGF (Epidermal Growth Factor) | |
|---|---|---|
| Typical Concentration | Typically used at 5-10% concentration. Apply twice daily to expression line areas (forehead, around eyes, between brows). Effects visible after 2-4 weeks. Must be used continuously — effects reverse when stopped. | Concentrations vary by product (typically measured in ppm or sh-oligopeptide-1 percentage). Applied once or twice daily. Best used after procedures or on aging skin. Apply before oils/occlusives. Store in refrigerator for stability. |
| Application | Topical (serum, cream). Water-soluble. Apply directly to expression line areas. | Topical (serum, cream, ampoule). Apply to clean skin. Temperature-sensitive — some products require refrigeration. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Argireline (Acetyl Hexapeptide-3)
Argireline (acetyl hexapeptide-3) mimics the C-terminal region of SNAP-25, a core SNARE complex component. The SNARE complex (SNAP-25, syntaxin, synaptobrevin) mediates vesicle fusion at the neuromuscular junction for acetylcholine release. Argireline competes with SNAP-25 for syntaxin binding, partially disrupting SNARE assembly and reducing neurotransmitter exocytosis. This decreases acetylcholine release and attenuates facial muscle contraction intensity. The effect is dose-dependent, localized, and reversible—unlike botulinum toxin's enzymatic cleavage of SNAP-25. Clinical studies show ~30% wrinkle reduction versus 80%+ with injectable neurotoxins. Provides non-invasive expression line softening.
EGF (Epidermal Growth Factor)
EGF binds EGFR/ErbB1 on keratinocytes and fibroblasts, triggering dimerization and autophosphorylation. Activates MAPK/ERK (Ras-Raf-MEK-ERK) and PI3K/AKT pathways, promoting proliferation, migration (actin reorganization, focal adhesion turnover), and differentiation. Upregulates cyclin D1, inhibits p27. Stimulates fibroblast collagen types I/III and hyaluronic acid via HAS2. In wound healing, accelerates re-epithelialization via keratinocyte migration and reduces scarring via TGF-beta modulation. For anti-aging, promotes cellular renewal and extracellular matrix production. Theoretical cancer concern from EGFR's growth role — topical EGF has not been shown to penetrate to basal layer or systemic circulation significantly.
Risks & Safety
Argireline (Acetyl Hexapeptide-3)
Common
Very well-tolerated. Occasional mild tingling.
Serious
None documented.
Rare
Allergic reaction. At very high concentrations, some users report a slight 'droopy' feeling in the treated area.
EGF (Epidermal Growth Factor)
Common
Very well-tolerated.
Serious
Theoretical concern about promoting growth of pre-existing skin cancers (unproven but debated).
Rare
Mild irritation.
Full Profiles
Argireline (Acetyl Hexapeptide-3) →
Known as 'topical Botox,' Argireline is a peptide that reduces the appearance of expression lines by partially inhibiting the SNARE complex — the same mechanism targeted by botulinum toxin, but through topical application rather than injection. The effect is much milder than Botox (roughly 30% wrinkle reduction vs 80%+) but provides a non-invasive option for forehead lines, crow's feet, and frown lines.
EGF (Epidermal Growth Factor) →
A signaling protein that stimulates cell growth, proliferation, and differentiation. In skincare, EGF promotes wound healing, skin renewal, and collagen production. Originally used in medical wound care and post-laser recovery, it has become popular in Korean skincare for anti-aging. It is one of the few growth factors with evidence for topical skincare efficacy.